Annual reports

 

2018 , 2019 

2017 ,  2016,  2015,  2014,  2013

More reports

REGENICS AGMs, BOARD meetings (password)

 

 

2021 

January 4th (e-GM notice)

Board 1-21 (Jan 18th)*

Board 2(3) (March 18th)*

Board 4 (April 22nd)*

* (unsigned) ** (protocol pending)

-------------------------- 

2020 

Board 8-20 (Dec. 16th)

Board 7-20 (Nov. 26th)

Board 6-20 (Oct. 16th)

October 16th (e-GM protocol)

Board 5-20 (Sep. 21th)

Board 4-20 (Sep. 1th)

Board 3-20 (Aug. 20th)

(June 24th), AGM protocol

Board 2-20 (June 16th)

Board 1-20 (March 9th)

--------------------------

2019 Annual Report 19 

Board 7-19 

Board 6-19

Board 5-19 AGM 2019

Board 4-19 

Board 3-19 

Board 2-19 

Board 1-19 eAGM-19

--------------------------

2018 Annual Report 18

Board 1-18 AGM-18

Board 2-18 eAGM-18

Board 3-18

Board 4-18

--------------------------

 2017 Annual Report 17

Board 1-17  AGM-17

Board 2-17  eAGM-17

e.o Board 1-17

 

          

 

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.